Georgian Scientists/ . 6  N 2, 2024 178

Georgian Scientists

Vol. 6  Issue 2, 2024

https://doi.org/10.52340/gs.2024.06.02.17

  1; 2; 3; 4; 
5

1  Phd ; Email:
teonaturashvili87@yahoo.com; 2 ; , Emai:

g.tevdorashvili@tsmu.edu;3

; E-mail: niniatevzadze1@gmail.com; 4

 Phd ; ; E-mail: shota.kepuladze@gmail.com;
https://orcid.org/0000-0002-5919-5581; 5

, ; E-mail:
burkadze@yahoo.com;  g.burkadze@tsmu.edu https://orcid.org/0000-0002-5028-4537

, 
.

. , 
,

. 
,  

, . , 

. 
, 

. 
. 

, 
-

.



Georgian Scientists/ . 6 N 2, 2024 179

, 
 (FFPE)  315 .

 E- , 
, 

, , 

. Beta-catenin- , 

. ,

. 
 P53- ,

,  P53- .

: ; ; EMT
; ;

, 
.

. 
, 

.1,2

, . 

.

.3 , 
, 

, 
, 

. ,
, ,

. ,

, . , 



Georgian Scientists/ . 6 N 2, 2024 180

, 
, 

.4

, 
, 

.  
 p53 .

, 
, 

. 
, 

, . , 

.

 ( ), 
. , 

, 
. 

, 
. 

 p53-
.

5 , , 
 p53-

, . 
. 

,  Ki67-
,  ( )

.6,7   
. ,

, 
 5%- ,

 Ki67 . 
. , 

.



Georgian Scientists/ . 6 N 2, 2024 181

.
, 

.8 , 

, 
.  5 

 80%- ), 
. 9

. 

, 

. 
, 

. 
, 

 Wnt-
.  Axin-2,  Wnt 

, .10

Axin-2-  in vivo 
 in vitro .

Axin-2 p
. , 

 Axin-2 
, 

.10 ,
Musashi-1-  (

) . in vitro
,  Musashi-1-

  .11 in  vivo
Musashi-1-

,  40%-
.11

.
,

. , 
,

, , .



Georgian Scientists/ . 6 N 2, 2024 182

, ,
, 

, .
. 

.   , 
.

, 
, , . 

, 

. , 
, 

. 
, ,

, 
. , 

, 
, 

. , 
, ,

, 
. , 

.12–

14

, 
.

, 
. 

, 
   , 

, 
, , , 

. , 
. 

. , , 
, 



Georgian Scientists/ . 6 N 2, 2024 183

,

. 12,15

. , 
 E- .

, , 
. 

, 
 E- . ,

, , ,
15.

, 
. , 

 E- , 
.  E- ,

 E- . 
, 

. , Wnt/ -
.16 ,

,  E -
. 

, 
 E - . 17,18

. ,  E-
.

,

 2019-2023 
.

, 
 (FFPE)  315 .

45  -  ;
45  - ;
45  - ;



Georgian Scientists/ . 6 N 2, 2024 184

45  - ;
45  - ;
45  - 
45  - 

 (H&E) , 
 QuPath- .

. 
.  NovolinkTM Max

Polymer Detection System.
H&E 

 ( ; .). 
:  Spearman rank

test-
Mann-Whitney  Kruskal-Wallis .   95%-

. P  <0.05 .
 SPSS statistical software V29.0-

.

 E-cadherin- , 
 (16,4±0,7) 

 (14,8±1,0),  (14,8±1,0). Beta-catenin-
 (21,4±1,2), 

 (41,4±1,3), 
 (16,4±0,9).  Vimentin-

 (36,7±1,2), 
 (41,5±0,9).

E-cadherin-
, 

 (18,4±1,2). 
,  (18,1±1,2). 

 Beta-catenin-
 (26,5±0,8), 

(36,4±1,3). 
,  (18,2±1,3). Vimentin-

 (24,8±1,2). 



Georgian Scientists/ . 6 N 2, 2024 185

, 
 (36,8±1,4).

 1. A. E-cadherin- , IHC, X100; B.  E-
cadherin- , IHC, X200; C. Beta-catenin-

, IHC, X200; D. Beta-catenin-
, IHC, X200; E. ,

IHC, X200; F. , IHC, X200;
 E-cadherin 

 (21,4±1,6). 
 (13,4±0,8). Beta-catenin-

  (9,8±1,1), 
 (56,7±1,5). 

 Beta-catenin-  (9,7±0,2). Vimentin-

 (19,4±1,5)  (17,3±1,0), 
 (60,4±1,6).

 Vimentin-  (28,7±0,6).



Georgian Scientists/ . 6 N 2, 2024 186

E-cadherin
Beta-
catenin

Vimentin

16,4±0,7 21,4±1,2 30,5±1,3

14,1±1,3 18,9±0,6 26,7±0,9

21,8±1,0 28,3±0,5 34,4±1,3

21±1,0 32,8±0,6 44,3±1,1

14,8±1,0 41,4±1,3 36,7±1,2

28,1±0,9 16,4±0,9 41,5±0,9

12,5±0,2 30,5±1,2 16,7±1,1

8,5±0,3 25,3±0,5 18,4±1,2

16.0±0,8 26,5±0,8 20,5±1,0

18,4±1,2 36,4±1,3 24,8±1,2

0 0 0

18,1±1,2 18,2±1,3 36,8±1,4

35,4±0,6 12,3±6,9 19,4±1,5

43,2±0,7 9,8±1,1 17,3±1,0

32,5±1,0 11,7±0,6 44,5±1,6

28,3±1,6 38,4±0,4 42,7±0,2

21,4±1,6 56,7±1,5 60,4±1,6

13,4±0,8 9,7±0,2 28,7±0,6

 1. E-cadherin- , Beta-catenin-  Vimentin-



Georgian Scientists/ . 6 N 2, 2024 187

P53-
) ,

 P53-  15,3±0,7. 
 CD44 

 (44,1±0,9), 
 (36,4±1,5) 

 (42,5±2,1).
 P53 

, 
(12,4±0,8),  (15,6±1,7). 

.  P53
 (15,7±1,2). CD44 

 (34,5±1,2),
, 

 (48,3±1,8).

 2. A. CD44- , IHC, X200; B. CD44-
, IHC, X200; C. P53-

, IHC, X200; D. P53- , IHC, X200.



Georgian Scientists/ . 6 N 2, 2024 188

 P53 
. 

(16,1±0,4)  (10,3±1,1). 
 (62,8±2,2).  CD44-

 (42,2±0,7), 
 (32,4±1,7), 

 (56,2±1,8)  (62,7±1,7).
P53 CD44

neg 38,7±1,3

neg 44,9±1,1

neg 43,1±1,1

neg 44,1±0,9

15,3±0,7 36,4±1,5

neg 42,5±2,1

neg 32,7±1,1

neg 36,2±0,7

12,4±0,8 34,2±1,5

15,6±1,7 34,5±1,2

0 0

15,7±1,2 48,3±1,8

neg 42,2±0,7

neg 32,5±0,9

neg 26,4±0,4

16,1±0,4 32,4±1,7

10,3±1,1 56,2±1,8

62,8±2,2 62,7±1,7

 2. P53-  CD44-



Georgian Scientists/ . 6 N 2, 2024 189

E-cadherin-  19-
,  22,9-

.

 29,1- ,  34,7-
, . 

 10,7- ,  16,5-
. 

 7,3- ,   
 9,9- , 

. 
, 

 6,6- .
 E-cadherin-

 14,7- , 
4,7- , 

.
Beta-catenin-

 9,1- , 
 18,2- .

9,1- ,  15,5-
, . 

 16,6- ,
 14,8-

. 
,  5.6- ,

 2-
. 

 15,3-
, . 

 6,7- , 
 8,5-

.
 11,1-

,   2,7-
, . 



 Georgian Scientists/ . 6  N 2, 2024 190

 9,4- ,  1,1-
. 

 10,1- , 
 24,-

. 
 1,7- , 

 20,9- ,
. 

 23,7-
. , 
 12,8- ,  8,1-

.

 1. E-cadherin- , Beta-catenin-  Vimentin-
 CD44-

 3,5- , 
 9,5- .

 12,4- ,
 3,7-

, . 
 14,9-



Georgian Scientists/ . 6 N 2, 2024 191

 7,8-
.   

 11,7- , 
 2,1-

, . 
 19,8-

. 
,  20,2- , 

 14,4-  CD44-
.

P53-
. 

. 
, ,

 0,5-
  . 

 P53-  5-
. 
. 

, 
,  P53-  47,1-

.



 Georgian Scientists/ . 6  N 2, 2024 192

 2. P53-  CD44-

E- , 
, , 

, 
. , E-

.
Beta-catenin- , 

. , Beta-

.
, 

, . 

. , 

.



Georgian Scientists/ . 6 N 2, 2024 193

CD44- , 
.

P53- , , 
, 

. 
P53-   , 

,  P53- .

:

1.D’Angelo, E. et al. Atypical Endometrial Hyperplasia, Low-grade: ‘much ADO about Nothing’.
American Journal of Surgical Pathology 45, 988–996 (2021).
2. Lax, S. F. [Precursor lesions of endometrial carcinoma]. Pathologe 40, 13–20 (2019).
3. Stringfellow, H. F. & Elliot, V. J. Endometrial metaplasia. Diagn Histopathol 23, 303–310 (2017).
4.Travaglino, A. et al. Endometrial Metaplastic/Reactive Changes Coexistent with Endometrial
Hyperplasia and Carcinoma: A Morphological and Immunohistochemical Study. Diagnostics (Basel)
12, (2021).
5. Hou, J. Y., McAndrew, T. C., Goldberg, G. L., Whitney, K. & Shahabi, S. A clinical and pathologic
comparison between stage-matched endometrial intraepithelial carcinoma and uterine serous
carcinoma: Is there a difference? Reproductive Sciences 21, 532–537 (2014).
6. Apostolou, G. et al. Cytodiagnosis of endometrial carcinoma and hyperplasia on imprint smears with
additional immunocytochemistry using Ki-67 and p53 biomarkers. Cytopathology 25, 86–94 (2014).
7.  Apostolou, G. et al. Utility of Ki-67, p53, Bcl-2, and Cox-2 biomarkers for low-grade endometrial
cancer and disordered proliferative/benign hyperplastic endometrium by imprint cytology. Diagn
Cytopathol 42, 134–142 (2014).
8. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J Clin 69, 7–34 (2019).
9.  Concin,  N. et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial
carcinoma. Int J Gynecol Cancer 31, 12–39 (2021).
10. Syed, S. M. et al. Endometrial Axin2+ Cells Drive Epithelial Homeostasis, Regeneration, and Cancer
following Oncogenic Transformation. Cell Stem Cell 26, 64-80.e13 (2020).
11. Falke, I. et al. Knockdown of the stem cell marker Musashi-1 inhibits endometrial cancer growth
and sensitizes cells to radiation. Stem Cell Res Ther 13, (2022).
12. Dongre, A. et al. Direct and Indirect Regulators of Epithelial–Mesenchymal Transition–Mediated
Immunosuppression in Breast Carcinomas. Cancer Discov 11, 1286–1305 (2021).
13. Wang, B., Li, X., Liu, L. & Wang, M. -Catenin: oncogenic role and therapeutic target in cervical
cancer. Biol Res 53, 33 (2020).
14.  Ramón  y  Cajal,  S. et al. Clinical  implications  of  intratumor  heterogeneity:  challenges  and
opportunities. J Mol Med 98, 161–177 (2020).



Georgian Scientists/ . 6 N 2, 2024 194

15.  Georgescu,  S.  R. et al. Tumour Microenvironment in Skin Carcinogenesis. in 123–142 (2020).
doi:10.1007/978-3-030-36214-0_10.
16. Chiu, H.-C., Li, C.-J., Yiang, G.-T., Tsai, A. & Wu, M.-Y. Epithelial to Mesenchymal Transition and
Cell Biology of Molecular Regulation in Endometrial Carcinogenesis. J Clin Med 8, 439 (2019).
17. Mittal, V. Epithelial Mesenchymal Transition in Tumor Metastasis. Annual Review of Pathology:
Mechanisms of Disease 13, 395–412 (2018).
18. Yeung, K. T. & Yang, J. Epithelial–mesenchymal transition in tumor metastasis. Mol Oncol 11, 28–
39 (2017).

Features of epithelial-mesenchymal transformation and distribution of stem cells during
Endometrial  ciliary/tubal metaplasia

Teona Turashvili1; George Tevdorashvili2; Nino Tevzadze3; Shota Kepuladze4; George Burkadze5

1MD, Phd Student at Tbilisi State medical University; 2Professor at Tbilisi State Medical University,
Gynecology and Obstetrics; 3Resident in Clinical Pathology at Tbilisi State medical University; 4Phd Student at
Tbilisi State medical University; AP/CP pathologist; MD; 5Professor at Tbilisi State Medical University, Head

of the Department of Molecular pathology;

Abstract
Metaplasia is an adaptive process in which one tissue is transformed into another tissue that is
functionally and morphologically different. The most common type of metaplasia in the endometrium
is ciliary/tubal metaplasia. Although the immunophenotype of ciliary/tubal metaplasia in the cervix is
well studied, there are very few studies related to endometrial metaplasia. There is no reliable clinical
evidence that tubal metaplasia is a precursor to serous carcinoma. It is highly likely that the precursor
may be a highly differentiated endometrioid carcinoma with extensive ciliary changes. In the
progression of endometrial pathologies, the role of epithelial-mesenchymal transformation is not
completely clear. Epithelial-mesenchymal transformation is also a probable cause of endometrioid-type
carcinomas. Within the framework of our research, a cohort retrograde study was carried out, for
which archival material of the teaching-scientific and diagnostic laboratory of Tbilisi State Medical
University was used.
Overall, the study included a total of 315 non-fixed formalin-fixed and paraffin-embedded (FFPE)
cases.
Our study showed that the expression analysis of E-cadherin showed that its expression was
significantly  decreased  in  the  study  groups,  in  contrast  to  the  study  groups  without  metaplasia,
indicating the independent behavior and importance of ciliary as well as atypical ciliary metaplasia in
endometrial carcinogenesis. Beta-catenin expression in ciliary metaplasia, as well as in atypical ciliary
metaplasia, increases progressively with the development of atypical processes in the endometrium.
Accordingly, vimentin can be used as an independent molecular marker for monitoring tubal
metaplasia.  A  lower  significance  of  P53-dependent  carcinogenesis  was  observed  in  endometrial
neoplastic processes, in contrast to serous carcinoma, where P53 expression is significantly higher.

Key words: endometrial metaplasia; Ciliary metaplasia; EMT transformation; stem cells;